Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 301
Tipo Título / Nombre Autor(es) Año
Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy Paiva B, Burgos L, González C..., Bergua Burgues JM 2025
Impact of molecular profile and variant allele frequency in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group Colmenares R, Barragán E, Rodríguez Veiga R..., Bergua Burgues JM 2025
Combinación del riesgo genético basal y el aclaramiento de la enfermedad residual para asignar el tratamiento post-remisión en los pacientes adultos con leucemia aguda linfoblástica (LAL) sin cromosoma filadelfia (PH-). Resultados finales del protocolo P LAL19 Ribera Santasusana J, Torrent Catarineu A, Morgades De La Fe M, Barrena Delfa S..., Bergua Burgués J 2025
Guía asistencial del Paciente Anciano-Paciente Unfit (Guía PAPU-70+) Montesinos P, Barragán E, Lloret P..., Bergua J, [C. científico y redacción] 2025
A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study Rodríguez-Veiga R, Gil C, Gil C, Gil C, Sobas M, Torres-Miñana L..., Bergua J 2025
Recomendaciones PETHEMA 2025 para el tratamiento de la leucemia mieloblástica aguda en pacientes ancianos (70+) y/o no no candidatos a quimioterapia intensiva (unfit). Guía asistencial Paciente Anciano Paciente Unfit (Guía PAPU-70+) Algarra L, Botella C, Vives S..., Bergua J 2025
Expression of the inhibitory checkpoints LAG-3, TIM-3, and PD-1 in NK cells and T cells in acute myeloid leukemia: preserved expression of LAG-3 is associated with patient survival Valhondo I, Pera A, Hassouneh F..., Bergua JM, Arcos MJ, Casas-Avilés I, Sánchez-García J, Serrano J, Durán E, Alonso C, Solana R, Tarazona R 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW..., Bergua Burgués JM 2025
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study Solana-Altabella A, Navarro-Vicente I, Rodríguez-Arbolí E, Noriega V, Serrano J..., Bergua-Burgues JM 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Gil C, Gil C, Martínez-Sánchez P..., Bergua JM 2025